Cadrenal Therapeutics Inc (CVKD)

Mar 2, 2026, 8:00 AM EST - 4 days ago

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Feb 24, 2026, 8:30 AM EST - 10 days ago

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Jan 12, 2026, 8:00 AM EST - 7 weeks ago

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Dec 30, 2025, 8:00 AM EST - 2 months ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Dec 29, 2025, 8:00 AM EST - 2 months ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Dec 17, 2025, 9:00 AM EST - 2 months ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Dec 12, 2025, 11:00 AM EST - 3 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 9:45 AM EST - 3 months ago

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Dec 11, 2025, 8:05 AM EST - 3 months ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Dec 1, 2025, 9:00 AM EST - 3 months ago

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PTCT

Nov 19, 2025, 8:00 AM EST - 3 months ago

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Nov 10, 2025, 9:00 AM EST - 4 months ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 29, 2025, 4:30 PM EDT - 5 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 15, 2025, 8:00 AM EDT - 6 months ago

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Aug 11, 2025, 8:00 AM EDT - 7 months ago

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 6:00 AM EDT - 7 months ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Jun 12, 2025, 8:00 AM EDT - 9 months ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 4, 2025, 8:00 AM EDT - 9 months ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

May 15, 2025, 7:30 AM EDT - 10 months ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 8, 2025, 8:00 AM EDT - 10 months ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Apr 17, 2025, 9:40 AM EDT - 11 months ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 4, 2025, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Feb 6, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 5, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Jan 9, 2025, 8:44 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 18, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Nov 19, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 12, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 7, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 1, 2024, 8:00 PM EDT - 1 year ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Oct 24, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 23, 2024, 9:00 AM EDT - 1 year ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 6, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Apr 11, 2024, 4:30 PM EDT - 2 years ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 9, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Mar 11, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update